Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|April 6, 2006
Multiple polyexponentials and quasipolynomials as empirical nonlinear regression models: a case study with HIV viral load dataL W Huson, J Chung, M SalgoJournal of Biopharmaceutical Statistics|January 16, 2007
Missing data imputation in two phase III trials treating HIV1 infectionL W Huson, J Chung, M SalgoJournal of Bacteriology|April 1, 1971
Salmonella locus affecting phosphoenolpyruvate synthase activity identified by a deletion analysisJ M Calvo, M Goodman, M Salgo, et al.The Journal of Infectious Diseases|January 1, 1991
Sensitive and specific detection of toxoplasma DNA in an experimental murine model: use of Toxoplasma gondii-specific cDNA and the polymerase chain reactionL M Weiss, S A Udem, M Salgo, et al.International Journal of Antimicrobial Agents|May 1, 1996
Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programmeG Moyle, A Goll, S Snape, et al.AIDS Research and Human Retroviruses|May 19, 2006
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2T Melby, P Sista, R DeMasi, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2000
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in EuropeG Moyle, A Pozniak, M Opravil, et al.The Journal of Infectious Diseases|May 1, 1997
Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 TeamS S Bakshi, P Britto, E Capparelli, et al.Journal of Virology|September 15, 2005
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitroM Mink, S M Mosier, S Janumpalli, et al.Critical Care Medicine|May 25, 2001
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patientsE Abraham, P F Laterre, J Garbino, et al.Pageof 2